Next-generation antibody therapeutics

The success of monoclonal antibodies as therapeutic modalities and improvements in antibody engineering technology have led to the further development of antibodies over the last few decades, resulting in the next generation of antibody-based therapeutics with which to tackle a litany of human diseases, including cancer. This next generation includes bi-specific antibodies, antibody–drug conjugates and nanobodies, among other types.

This In Focus, supported by Sino Biological US Inc. (PA, USA), explores the structure, capabilities and mechanisms of action for each of these three next-generation antibody types, providing an essential update to progress in the field and the advantages and challenges of each modality.